• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

ADHD Medication During Pregnancy and Breastfeeding

The decision to stop or keep ADHD medication during pregnancy and nursing is a challenge for women suffering from the condition. There aren't enough data on how exposure to ADHD for a long time could affect a pregnant fetus.

A recent study published in Molecular Psychiatry demonstrates that children exposed to ADHD uk medication for adhd during pregnancy do not develop neurological problems like hearing loss or vision, febrile seizures, or IQ impairment. The authors acknowledge the need for more high-quality studies.

Risk/Benefit Analysis

Women who are pregnant and taking ADHD medication should evaluate the benefits of using it versus the risks best medicine for adhd and social anxiety the fetus. Doctors don't have the necessary data to give clear guidelines, but they can provide information on risks and benefits that aid pregnant women in making informed decisions.

A study published in Molecular Psychiatry concluded that women who took ADHD medication during their early pregnancy were not at a greater risk of fetal malformations, or structural birth defects. Researchers conducted a large, population-based case-control study to assess the risk of major structural birth defects in babies born to mothers who had taken stimulants in the early stages of pregnancy and those who had not. Pediatric cardiologists, clinical geneticists and other experts examined the cases to make sure that the classification was accurate and to minimize any bias.

The research conducted by the researchers was not without limitations. The researchers were unable, in the first place to distinguish the effects caused by the medication from the disorder. This limitation makes it difficult to know whether the small associations observed in the exposed groups are due to medication use or confounding by comorbidities. In addition the study did not look at the long-term outcomes of offspring.

The study did reveal that infants whose mothers had taken ADHD medication during pregnancy were at a more risk of being admitted to the neonatal intensive care unit (NICU) than those who were born without any medication or had taken off their medication prior to or during pregnancy. This was due to central nervous system disorders. The higher risk of admission was not influenced by the stimulant medications used during pregnancy.

Women who used stimulant ADHD medication during pregnancy also had an increased risk of having a caesarean section or having a baby born with a low Apgar score (less than 7). These increases appeared to be independent of the type of medication taken during pregnancy.

Researchers suggest that the minor risks posed by the use of ADHD medications during early pregnancies can be offset by greater benefits to both mother and baby of continuing treatment for the woman's condition. Physicians should discuss this with their patients and, if they are able, assist them in developing strategies to improve coping skills which can reduce the effects of her disorder on her daily functioning and relationships.

Medication Interactions

Doctors are increasingly faced with the decision of whether to continue treatment or stop it during pregnancy as more women are diagnosed with safest adhd medication. Often, these decisions are made in the absence of solid and reliable evidence either way, so physicians have to weigh their experience, the experiences of other doctors, and what the research suggests about the subject and their own judgments for each individual patient.

The issue of risk for infants can be difficult to determine. The research on this subject is based on observation rather than controlled studies, and a lot of the results are in conflict. The majority of studies restrict their analysis to live-births, which could underestimate the severity of teratogenic effects which can cause terminations or abortions of pregnancy. The study discussed in the journal club addresses these limitations, by examining both the data from deceased and live births.

The conclusion: While some studies have shown an association between ADHD medications and the possibility of certain birth defects, others have found no connection and the majority of studies have a neutral or slightly negative impact. In the end, a careful risk/benefit assessment must be conducted in every situation.

For many women with ADHD and ADD, the decision to discontinue medication can be difficult, if not impossible. In an article published in the Archives of Women's Mental Health psychologist Jennifer Russell notes that stopping ADHD medication during pregnancy can lead to increased depression, feelings of loneliness and family conflict for those suffering from the disorder. The loss of medication can affect the ability to safely drive and to perform work-related tasks which are vital aspects of normal life for people with adhd and anxiety medication.

She recommends women who are uncertain about whether or not to stop medication in light of their pregnancy should consider informing family members, friends, and coworkers on the condition, its impact on daily functioning, and on the advantages of staying on the current treatment plan. It can also help a woman feel confident about her decision. It is important to note that certain drugs can pass through the placenta so if the patient decides to stop her ADHD medication during pregnancy and breastfeeding, she must be aware of the possibility that traces of the drug could be passed on to the baby.

Birth Defects and Risk of

As the use and misuse of ADHD drugs to treat symptoms of attention deficit hyperactivity disorder (ADHD) increases, so does concern about the potential effects of these drugs on fetuses. Recent research published in the journal Molecular Psychiatry has added to the body of knowledge regarding this topic. Utilizing two huge data sets researchers were able analyze more than 4.3 million pregnancies to determine whether stimulant medication use increased the risk of birth defects. Researchers discovered that although the risk overall is low, first-trimester ADHD medication exposure was associated with slightly higher rates of certain heart defects, such as ventriculoseptal defect.

The authors of the study found no link between early medication use and congenital abnormalities such as facial clefting or club foot. The results are consistent with previous studies revealing a small but significant increase in the risk of heart malformations among women who started taking ADHD medications prior to the time of the birth of their child. The risk increased in the latter half of pregnancy when many women began to stop taking their medication.

Women who took ADHD medications during the first trimester of their pregnancy were also more likely to undergo caesarean sections, a low Apgar score after delivery and a baby who required breathing assistance at birth. The authors of the study were not able to remove bias in selection since they limited the study to women who did not have any other medical conditions that could have contributed to the findings.

The researchers hope their research will serve to inform the clinical decisions of physicians who see pregnant women. They advise that while the discussion of risks and benefits is important but the decision to stop or continue treatment should be based on the woman's requirements and the severity of her ADHD symptoms.

The authors also caution that while discontinuing the medications is an alternative, it is not an option that is recommended due to the high rate of depression and other mental health problems among women who are pregnant or recently post-partum. Further, research shows that women who stop taking their medication will have a difficult adjustment to life without them after the baby is born.

Nursing

It can be a challenge becoming a mother. Women who suffer from ADHD who have to deal with their symptoms while attending doctor appointments and preparing for the arrival of a baby and getting used to new routines at home can experience severe challenges. This is why many women elect to continue taking their strattera Adhd medication medications throughout pregnancy.

The majority of stimulant medications are absorbed through breast milk in low amounts, so the risk to the infant who is breastfeeding is low. However, the amount of medication exposure to the newborn can vary depending on dosage, frequency it is administered and the time of the day it is administered. In addition, different drugs enter the infant's system via the gastrointestinal tract, or through breast milk. The impact of these medications on the health of a newborn is not completely understood.

Some doctors may decide to stop stimulant medications during a woman's pregnancy due to the absence of research. This is a difficult decision for the patient, who must weigh the benefits of continuing her medication against the potential risks to the fetus. Until more information becomes available, doctors can inquire about pregnant patients whether they have an background of ADHD or if they intend to take medication in the perinatal period.

Numerous studies have proven that women can continue taking their ADHD medication safely during pregnancy and breast-feeding. In response, an increasing number of patients are choosing to continue their medication. They have concluded through consultation with their doctors, that the benefits of keeping their current medication far outweigh any risk.

Women with ADHD who are planning to nurse should seek the advice of a specialist psychiatrist prior to becoming pregnant. They should discuss their medication with their physician and discuss the advantages and disadvantages of continued treatment, including non-pharmacological strategies. Psychoeducation is also needed to help pregnant women with ADHD be aware of the symptoms and the underlying disorder. They should also be informed about treatment options and reinforce coping mechanisms. This should be a multidisciplinary process with the GPs, obstetricians and psychiatrists. Pregnancy counseling should consist of a discussion of a treatment plan for the mother and the child, as well as monitoring for signs of deterioration, and, if needed adjustments to the medication regimen.